Three-step monoclonal antibody tumor targeting in carcinoembryonic antigen-positive patients.
Giovanni Paganelli(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), E. Seccamani(Biomedica (Czechia)), Patrizia Magnani(IRCCS Ospedale San Raffaele), F. Chiolerio, Massimo Malcovati(University of Milan), Emmanuel Villa(Fondazione Poliambulanza Istituto Ospedaliero), Claudio Rossetti(University of Milan), Felicia Zito(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), F. Sudati(University of Milan), Lucia Lopalco(Vita-Salute San Raffaele University)
PubMed
November 1, 1991
Cited by 247
Related Papers
Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors
|European Journal of Nuclear Medicine and Molecular Imaging|2014|465
Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs.
|PubMed|2005|375
Control of HIV despite the Discontinuation of Antiretroviral Therapy
|New England Journal of Medicine|1999|328
Immunization with HIV-1 gp41 Subunit Virosomes Induces Mucosal Antibodies Protecting Nonhuman Primates against Vaginal SHIV Challenges
|Immunity|2011|285
Mucosal and Plasma IgA from HIV-1-Exposed Uninfected Individuals Inhibit HIV-1 Transcytosis Across Human Epithelial Cells
|The Journal of Immunology|2000|244